-
SRPT Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Sarepta Therapeutics (SRPT)
Company Profile
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.12 bn | 1.12 bn | 1.12 bn | 1.12 bn | 1.12 bn | 1.12 bn |
Cash burn (monthly) | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) | 17.15 mm |
Cash used (since last report) | n/a | n/a | n/a | n/a | n/a | 62.24 mm |
Cash remaining | n/a | n/a | n/a | n/a | n/a | 1.06 bn |
Runway (months of cash) | n/a | n/a | n/a | n/a | n/a | 61.6 |
13F holders | Current |
---|---|
Total holders | 462 |
Opened positions | 80 |
Closed positions | 77 |
Increased positions | 154 |
Reduced positions | 156 |
13F shares | Current |
---|---|
Total value | 10.03 tn |
Total shares | 87.95 mm |
Total puts | 1.20 mm |
Total calls | 1.42 mm |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
BlackRock | 11.19 mm | $1.36 tn |
Vanguard | 9.09 mm | $1.10 tn |
Capital International Investors | 8.70 mm | $1.06 tn |
JHG Janus Henderson | 4.33 mm | $526.20 bn |
STT State Street | 4.07 mm | $494.85 bn |
Farallon Capital Management | 2.87 mm | $348.37 bn |
Avoro Capital Advisors | 2.56 mm | $310.73 bn |
BK The Bank of New York Mellon Corporation | 2.15 mm | $260.87 bn |
Wellington Management | 2.07 mm | $251.54 bn |
JPM JPMorgan Chase & Co. | 2.02 mm | $245.69 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Mar 25 | Claude Nicaise | Common Stock | Sell | Dispose S | No | No | 99.64 | 2,491 | 248.20 k | 27,812 |
12 Mar 25 | Claude Nicaise | Common Stock | Option exercise | Acquire M | No | No | 25.18 | 9,746 | 245.40 k | 30,303 |
12 Mar 25 | Claude Nicaise | Stock Options Common Stock | Option exercise | Dispose M | No | No | 25.18 | 9,746 | 245.40 k | 0 |
10 Mar 25 | Connelly Deirdre P | Common Stock | Grant | Acquire A | No | No | 0 | 2,383 | 0.00 | 5,225 |
10 Mar 25 | Connelly Deirdre P | Stock Options Common Stock | Grant | Acquire A | No | No | 99.69 | 4,792 | 477.71 k | 4,792 |
10 Mar 25 | Hans Lennart Rudolf Wigzell | Common Stock | Grant | Acquire A | No | No | 0 | 2,383 | 0.00 | 25,223 |
10 Mar 25 | Hans Lennart Rudolf Wigzell | Stock Options Common Stock | Grant | Acquire A | No | No | 99.69 | 4,792 | 477.71 k | 4,792 |
10 Mar 25 | Stephen Mayo | Common Stock | Grant | Acquire A | No | No | 0 | 2,383 | 0.00 | 9,004 |
10 Mar 25 | Stephen Mayo | Stock Options Common Stock | Grant | Acquire A | No | No | 99.69 | 4,792 | 477.71 k | 4,792 |
10 Mar 25 | Claude Nicaise | Common Stock | Grant | Acquire A | No | No | 0 | 2,383 | 0.00 | 20,557 |